RxDoctor Payments Data

Lea Gottfredsen

Internal Medicine · Rochester, NHNPI 1831187723

Payments from drug & device makers

$484in general payments, 2019–2025

Across 12 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$236
  • GSK$79
  • Novo Nordisk$66
  • Boehringer Ingelheim$28
  • Astellas Pharma US Inc$24
  • Pfizer$23
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484 in reported general payments places this provider in the 85th percentile of 504 internal medicine providers in New Hampshire.

See all internal medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$66,394
Medicare patients
303
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$67,919
TrulicityDulaglutide39$60,707
JardianceEmpagliflozin38$55,408
OzempicSemaglutide25$44,428
JanuviaSitagliptin Phosphate40$41,727
XareltoRivaroxaban12$16,634
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$14,015
Lansoprazole16$5,859
Serevent DiskusSalmeterol Xinafoate11$4,536
SynthroidLevothyroxine Sodium97$3,828
Advair DiskusFluticasone Propion/Salmeterol15$3,199
Rosuvastatin Calcium184$3,159
Atorvastatin Calcium461$3,052
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,577
Levothyroxine Sodium316$2,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$67,91956 claims
Boehringer IngelheimJardiance$28$55,40838 claims
Novo NordiskOzempic$66$44,42825 claims
Johnson & JohnsonXarelto$13$16,63412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 internal medicine providers in New Hampshire.

Other internal medicine in Rochester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →